Gilead's hepatits C treatment dropped by Express Scripts

Prescription drug benefit manager Express Scripts Holding Co. (Nasdaq: ESRX) will no longer cover Gilead Sciences Inc.'s (Nasdaq: GILD) hepatitis C treatment Sovaldi beginning January 1. Shares of Express Scripts climbed $1.36 to close at $82.33 while Gilead stock plummeted $15.55 to close at $92.90.